Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

benzinga.com/general/biotech/25/05/45179856/alnylam-delivers-q1-surprise-analysts-highlight-amvuttra-momentum-and-limited-tariff-risk

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03).
The company reported quarterly sales of $594.2 million, up 20% year over year, beating the consensus of $585.8 million.
Net product…

This story appeared on benzinga.com, 2025-05-02 21:04:50.